Optimizing Outcomes for Patients With Curable Bladder Cancer

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

In this video, Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center in Philadelphia, discusses highlights of a session on bladder cancer from the 2017 Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Dr. Plimack chaired the session, which focused on optimizing outcomes in muscle-invasive bladder cancer, and gave a presentation on genomic markers of response to neoadjuvant chemotherapy. Emerging data on alterations in DNA repair genes and their association with outcomes are informing clinical trial designs with the aim of studying the feasibility of reducing treatment burden for this patient population.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy

January 1st 2024
Podcast

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

miRNA Assay May Lead to Early Detection in PDAC

April 8th 2024
Article

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors

April 8th 2024
Article

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.